Key statistics
On Friday, Cullinan Therapeutics Inc (CGEM:NSQ) closed at 18.15, 137.57% above the 52 week low of 7.64 set on Dec 12, 2023.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 17.95 |
---|---|
High | 18.62 |
Low | 17.51 |
Bid | 16.62 |
Offer | 19.80 |
Previous close | 17.94 |
Average volume | 766.49k |
---|---|
Shares outstanding | 57.98m |
Free float | 54.70m |
P/E (TTM) | -- |
Market cap | 1.05bn USD |
EPS (TTM) | -3.10 USD |
Data delayed at least 15 minutes, as of Sep 20 2024 21:00 BST.
More ▼
- Cullinan Therapeutics Receives Approval to Initiate its Global Phase 1 Clinical Trial of CLN-978 for the Treatment of Systemic Lupus Erythematosus
- Cullinan Therapeutics Announces Submission of Investigational New Drug Application to U.S. Food and Drug Administration for CLN-978 to Treat Systemic Lupus Erythematosus
- Cullinan Therapeutics Presents Positive Updated Data from Module C of Zipalertinib Pivotal Phase 2b Study at ESMO 2024
- Cullinan Therapeutics to Participate in Upcoming Investor Conferences
- Cullinan Therapeutics Provides Corporate Update and Reports Second Quarter 2024 Financial Results
- Cullinan Therapeutics Announces Positive Initial Data from Pivotal Phase 2b REZILIENT1 Study of Zipalertinib
- Cullinan Therapeutics to Participate in Fireside Chat at TD Cowen 5th Annual Oncology Innovation Summit
- Cullinan Therapeutics to Present First Data for CLN-619, a Novel Anti-MICA/B Antibody, in Combination with a Checkpoint Inhibitor and Updated Monotherapy Data at ASCO 2024
- Cullinan Therapeutics Provides Corporate Update and Reports First Quarter 2024 Financial Results
- Cullinan Therapeutics Announces Appointment of Mary Kay Fenton as Chief Financial Officer
More ▼